Tasso, Inc.

Key People

• Ben Casavant - CEO & Co-Founder
• Erwin Berthier - CTO & Co-Founder
• Monica Williams - Chief Financial Officer
• Matt Cook - Senior Vice President, Commercial
• Ann-li Cooke - Vice President of Product
• Wendy Harman - Vice President of Product Marketing
• Julien Rohel - Vice President of Operations
• Hal Grubbs - Vice President of Manufacturing

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in medical technology and business development.

The co-founders, Ben Casavant and Erwin Berthier, have significant experience in the medical technology sector, contributing to the company's innovative approach to at-home diagnostics.

Clinical Need

Aspect: Very Strong
Summary: Tasso addresses a significant need for convenient, at-home blood collection solutions.

By enabling patients to collect blood samples at home, Tasso's devices reduce the need for clinic visits, improving patient compliance and expanding access to diagnostic testing.

Competition

Aspect: First mover
Summary: Tasso is among the pioneers in the at-home blood collection market.

While Tasso's early entry allows it to establish market presence, it also faces the task of educating the market and overcoming initial adoption barriers.

Technical Challenge

Aspect: Predictable
Summary: The technology behind Tasso's devices is well-understood and manageable.

Tasso's devices utilize established microfluidic technologies, reducing the likelihood of unforeseen technical issues during production and deployment.

Patent

Aspect: Strong
Summary: Tasso holds a robust patent portfolio protecting its innovations.

The patents cover key aspects of Tasso's blood collection technology, deterring competitors and supporting the company's market position.

Financing

Aspect: Well-funded
Summary: Tasso has secured substantial funding from reputable investors.

The $100 million Series B investment led by RA Capital Management enables Tasso to scale operations and enhance product offerings.

Regulatory

Aspect: 510k/PMA
Summary: Tasso's products have obtained necessary regulatory approvals.

Achieving FDA clearance for its devices allows Tasso to market its products in the U.S., ensuring compliance with safety and efficacy standards.

Opportunity Rollup

Odds of Success

3.3

Peak Market Share

3.9

Segment CAGR

1.9%

Market Segment

In Vitro Diagnostics

Market Sub Segment

At-Home Blood Collection Devices

Key Takeaway

Tasso, Inc. is well-positioned to capitalize on the growing demand for at-home diagnostic solutions, leveraging its innovative technology and strong financial backing to address a significant clinical need.